Clinical Trial Detail

NCT ID NCT02401347
Title Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Melinda Telli
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: adult

Additional content available in CKB BOOST